Results 21 to 30 of about 17,802 (177)

Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin [PDF]

BioImpacts, 2023
Introduction: Fingolimod is a drug that is used to treat multiple sclerosis (MS). It has pH-dependent solubility and low solubility when buffering agents are present.
Samira Gholizadeh, Hossein Haghaei, Hosna Karami, Somaieh Soltani, Mostafa Zakariazadeh, Javad Shokri   +5 more
doaj   +1 more source

Fingolimod Inhibits Inflammation but Exacerbates Brain Edema in the Acute Phases of Cerebral Ischemia in Diabetic Mice

Frontiers in Neuroscience, 2020
Background and Purpose: Diabetes mellitus increases stroke incidence and mortality and hampers functional recovery after stroke. Fingolimod has been shown to improve neurofunctional recovery and reduce brain infarction after ischemic injury in mice ...
Wanlu Li, Tingting He, Tingting He, Lu Jiang, Rubing Shi, Yaying Song, Yaying Song, Muyassar Mamtilahun, Yuanyuan Ma, Yuanyuan Ma, Zhijun Zhang, Yaohui Tang, Guo-Yuan Yang, Guo-Yuan Yang, Yongting Wang   +14 more
doaj   +1 more source

Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis [PDF]

, 2017
Charlotte Druart, Souraya El Sankari, Vincent van Pesch Neurology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium Abstract: With a growing number of disease-modifying therapies becoming ...
Van Pesch, Vincent, Druart C, van Pesch V, Souraya El Sankari, El Sankari S, Vincent van Pesch, Druart, Charlotte, Charlotte Druart, El Sankari, Souraya   +8 more
core   +1 more source

Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis

Neurobiology of Disease, 2015
Multiple sclerosis (MS) is a major demyelinating disease of the central nervous system (CNS) leading to functional deficits. The remyelination process is mediated by oligodendrocyte progenitor cells (OPCs).
Jing Zhang, Zheng Gang Zhang, Yi Li, Xiaoshuang Ding, Xia Shang, Mei Lu, Stanton B. Elias, Michael Chopp   +7 more
doaj   +1 more source

Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study

, 2017
Objectives: Adherence to multiple sclerosis (MS) treatment is essential to optimize the likelihood of full treatment effect. This prospective, observational, single-center cohort study investigated adherence to fingolimod over the 2 years following ...
Michael Coslovsky, Ivo Abraham, Abraham, Ivo, Zimmer, Andrea, Décard, Bernhard F, Andrea Zimmer, Bernhard F Décard, Coslovsky, Michael   +7 more
core   +2 more sources

Cardiovascular effects of fingolimod: Relevance, detection and approach

Revista Portuguesa de Cardiologia, 2015
Fingolimod, a structural analogue of sphingosine, is the first oral treatment available for multiple sclerosis. The presence of sphingosine-1-phosphate receptors in the sinus and atrioventricular nodes, myocardial cells, endothelial cells and arterial ...
Carlos Aguiar, Sónia Batista, Ricardo Pacheco   +2 more
doaj   +1 more source

Effects of fingolimod on heart injury induced by renal ischemia-reperfusion [PDF]

مجله پزشکی دانشگاه علوم پزشکی تبریز
Background. Renal ischemia-reperfusion injury (IRI) is one of the inevitable complications of surgery. The evidence shows that fingolimod, with its anti-inflammatory effects, can play a protective role in renal IRI.
Bahram Niknafs, Yasin Bagheri, Seyyedeh Mina Hejazian, Parya Niknafs, Neda Roshanravan, Mohammadreza Ardalan, Sepideh Zununi Vahed   +6 more
doaj   +1 more source

The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia

Journal of Neuroinflammation, 2021
Background The role of the immune system in stroke is well-recognised. Fingolimod, an immunomodulatory agent licensed for the management of relapsing-remitting multiple sclerosis, has been shown to provide benefit in rodent models of stroke.
Kyle Malone, Andrea C. Diaz Diaz, Jennifer A. Shearer, Anne C. Moore, Christian Waeber   +4 more
doaj   +1 more source

Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis

, 2015
Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability.
A. Ghazaryan, Rossini, Paolo Maria, S. Vollaro, Mulas, Delia, P. M. Rossini, Pasqualetti, Patrizio, D. Mulas, D. Landi, G. Pellegrino, E. Falato, P. Pasqualetti, M. M. Filippi   +11 more
core   +1 more source

Multiple Sclerosis Relapses Following Cessation of Fingolimod

, 2022
BACKGROUND: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new ...
Hodgkinson, S, Alroughani, R, Izquierdo, G, Eichau, Sara, Skibina, Olga, Patti, F, Malpas, Charles B, Horakova, D, Roos, I, Malpas, CB, Izquierdo, Guillermo, Lechner-Scott, J, Sharmin, Sifat, Lechner-Scott, Jeannette, Butzkueven, Helmut, Patti, Francesco, Sharmin, S, Skibina, O, Alroughani, Raed, Butzkueven, H, Havrdova, EK, Hodgkinson, Suzanne, Buzzard, K, Kappos, Ludwig, Grammond, P, Havrdova, Eva Kubala, Buzzard, Katherine, MSBase Study Group, Kalincik, T, Roos, Izanne, Grammond, Pierre, Kappos, L, Kalincik, Tomas, Eichau, S, Horakova, Dana   +34 more
core   +1 more source